PAO Group, Inc. (OTC Pink: PAOG) has announced plans to soon launch a CBD nutraceuticals line of products expected to generate revenue this year, in 2021. Today the company highlights CBD industry momentum that could benefit PAOG’s impending CBD nutraceuticals product launch.

PAOG is developing CBD pharmaceutical and nutraceuticals from its intellectual property associated with a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”

The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027.

A recently published article on the growing CBD market highlights some “mainstream” company CBD initiatives the PAOG management views as beneficial to the PAOG CBD nutraceuticals product launch. PAOG management anticipates “mainstream” initiatives to validate their own products and even bring more attention to their products by simply bring more attention to the overall market.

Growing CBD Market Lures Mainstream Businesses

The article includes mention of Herbalife Nutrition, Procter & Gamble Co., Aurora Cannabis and recently IPO’d Grove, Inc.

PAOG’s CBD nutraceutical developments stem from the company’s long-term CBD pharmaceutical initiative built on a CBD intellectual property acquisition from Nouveau Life Pharmaceuticals.

Learn more about PAOG at